Web Flow - Login to access your portal

PCI Pharma Services Announces Significant expansion in Serialization technology

We are pleased to announce a significant expansion of our market leading Serialization capability. We will increase Serialization capacity across our global supply network to support clients in advance of meeting both US DSCSA and EU FMD implementation dates.

PCI Serialization Expansion

We have been actively serializing commercial products for both domestic and international markets for the past five years, with products destined for North America and Europe, in addition to emerging market geographies such as South Korea, Turkey, Brazil, China and others. In total, PCI supports medicines destined to over 100 global countries. Our expansion triples our global Serialization capacity in advance of upcoming DSCSA and FMD requirements.

PCI has partnered with Antares Vision, Marchesini and Domino for this latest installation, utilizing Antares’ leading Serialization platform and technology architecture across a variety of Serialization technology platforms and applications. The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.

In addition, Serialization technologies support ancillary and tertiary packaging, corrugated shippers and palletization solutions for supporting multi-level product aggregation. Aggregation is technically not a requirement for compliance to the 2017 DSCSA deadline, however PCI has strongly supported the advanced use of aggregation to realize significant benefits in packaging operations as well as the broader pharmaceutical supply chain.

Commenting on the expansion, Vice President of Global Engineering, Ken Richardson shared: “Serialization preparedness is the topic on everyone’s mind in the pharmaceutical industry. We are very excited about the next phase of our global Serialization initiative and brand security program here at PCI. Having active developed and supported Serialization over the past five years with numerous commercial applications around the world, we have a significant body of knowledge to share with clients. With these key learnings from practical applications of Serialization and anti-counterfeiting technologies, we have positioned ourselves to support our clients as they start to truly develop their own global Serialization strategies.

This latest investment is considerable, and features what we believe are truly industry-leading technologies. The spotlight is on the industry to meet the November deadline and PCI has directed an amazing amount of financial resource, technological expertise and manpower to help our clients be prepared.

The announcement of our recent Serialization expansion complements an announcement in late 2016 of our investment in site capacity expansion for our market leading commercial contract packaging services. Sites in Philadelphia and Rockford added multiple primary packaging lines including blister packaging, bottling, and pouch/sachet filling technologies as demand continues to grow for outsourced packaging services.

In addition, over the past 18 months we have hosted regional Serialization Forums in geographical pharmaceutical concentrations including Philadelphia, Boston, Research Triangle Park (RTP) North Carolina, Chicago/Rockford, San Diego, San Francisco, and most recently London, drawing considerable crowds and interest. Future venues and dates will be announced in coming months and interested attendees are encouraged to follow PCI’s social media channels including Twitter and LinkedIn for more details.

To learn more about the upcoming serialization implementation dates,contact us

Posted on Categories News

Leave a Reply

Your email address will not be published. Required fields are marked *

thirteen + 16 =

Explore the PCI Process Phase by Phase

PRE-CLINICAL
PHASE I
PHASE II
PHASE III
COMMERCIAL

Swipe to explore the PCI Process

PRE CLINICAL

pre-clinical-icon
  • Formulation Development
  • Analytical development/characterisation

PHASE 1

PCI Phase 1
  • Formulation Development
  • Analytical Development
  • Drug in capsule/vial technology (Xcelodose)®
  • Phase I product manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase I packaging and labelling
  • Storage and distribution

PHASE 2

PCI Phase 2
  • Formulation Optimization
  • Dosage Form Process Validation
  • Analytical Testing and Stability Services
  • Phase II Product Manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase II packaging and labelling
  • Storage and distribution

PHASE 3

PCI Phase 3
  • Comparator Sourcing
  • Scale Up Studies
  • Phase III Product Manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase III packaging and labelling
  • Analytical testing and stability services
  • Storage and distribution

COMMERCIAL

PCI Commercial Phase
  • Scale up for commercial supply
  • Commercial product manufacture
  • Commercial packaging and labelling
  • Validation services
  • Analytical testing and stability services
  • Product release to market
  • Storage and distribution

PCI Points...

You told us what aspects you value as "very important" when choosing a vendor...

Why choose us...

Our global reach and localized support ensures PCI as a strategic partner remains focussed on delivering speed-to-market and the commercial success of our customers

PCI is a global company that focusses on delivering speed-to-market and the commercial success of our customers

Why choose us...